According to obesity treatment guidelines, inadequate response is generally defined as less than 5% body weight reduction after 12 weeks at a therapeutic dose, though this is not a specific FDA requirement for tirzepatide
Additionally, the FDAs adverse event reporting system has noted NAION cases linked to semaglutide, though the data is not yet sufficient to establish causality
Heres why Sant Clinics stands out: Board-certified medical team with 7+ specialist doctors 10,000+ patients treated with proven results 4.9 Google rating among the highest-rated clinics in Spain Premium location on Avenida Diagonal, Barcelonas most prestigious avenue Multilingual staff English, Spanish, Portuguese, and Russian Free aesthetic consultation to discuss your goals Benefits of GLP-1 Weight Loss Significant weight loss Appetite regulation Metabolic improvement Medical supervision Sustainable results with lifestyle changes Who Is GLP-1 Weight Loss Ideal For
And it happens more often than you'd think
Our improved understanding of the complex biological regulation of appetite, metabolism and body weight, involving co-ordinated responses between peripheral tissues and central appetite-regulating centres, has resulted in the availability of nine Food and Drug Administration (FDA) (liraglutide, semaglutide, tirzepatide, orlistat, phentermine, phentermine/topiramate, bupropion-naltrexone, setmelanotide, and metreleptin), and seven European Medicine Agency (EMA) (excluding phentermine and phentermine/topiramate), approved AOMs
